scholarly journals Holmium:YAG Laser for the Treatment of Genital and urethral Warts: Multicentre Prospective Evaluation of Safety and Efficacy

2021 ◽  
Vol 12 (1) ◽  
pp. e34-e34
Author(s):  
Michele Del Zingaro ◽  
Giovanni Cochetti ◽  
Alessandro Zucchi ◽  
Alessio Paladini ◽  
Jacopo Adolfo Rossi De Vermandois ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Yttrium Aluminium Garnet ◽  
Safety And Efficacy ◽  
Prospective Multicentre Study ◽  
Patient Global Impression ◽  
Quality Of Life Index ◽  
Treatment Naïve ◽  
Improve Patient

Introduction: Genital condylomatosis is a highly contagious disease caused by the human papilloma virus (HPV). The aim of this prospective multicentre study was to evaluate the safety and efficacy of the Holmium:YAG (yttrium-aluminium-garnet) laser in the treatment of genital and intra-urethral warts; the secondary aim was to assess the patients’ postoperative satisfaction and cosmetic results. Methods: From December 2016 to March 2019, patients with genital warts were prospectively enrolled in three hospitals. The inclusion criteria were male gender, age over 18 years-old and treatment-naïve. External and urethral genitalia warts were treated by the Holmium YAG laser. The follow-up analysis consisted of physical examination, flexible urethro-cystoscopy in case of meatal lesions, and administration of Dermatology Quality of Life Index (DLQI) and Patient Global Impression of Improvement (PGI-I) questionnaires at 1, 3, 6 and 12 months after surgery and subsequently yearly. Results: Sixty patients were enrolled. The single treatment was effective in 57/60 patients (95%). At a mean follow-up of 26 months, recurrences occurred in 8 patients (13.3%). No peri- or post-operative complication occurred. An improvement in pre-operative condition was highlighted with PGI-I and DLQI questionnaires. Conclusion: Our prospective multicentre study showed that holmium laser surgery seems to be a safe and effective treatment for external genital and urethral warts. Good dermatological outcomes aid to further improve patient satisfaction.

scholarly journals Safety and efficacy of venoplasty in MS

Neurology ◽  
2018 ◽  
Vol 91 (18) ◽  
pp. e1660-e1668 ◽  
Author(s):  
Anthony L. Traboulsee ◽  
Lindsay Machan ◽  
J. Marc Girard ◽  
Jean Raymond ◽  
Reza Vosoughi ◽  
...  
Keyword(s):  
Patient Reported Outcome ◽  
Safety And Efficacy ◽  
Safety Outcome ◽  
Efficacy Outcome ◽  
Patient Reported ◽  
To Receive ◽  
Improve Patient

ObjectiveTo determine the safety and efficacy of balloon vs sham venoplasty of narrowing of the extracranial jugular and azygos veins in multiple sclerosis (MS).MethodsPatients with relapsing or progressive MS were screened using clinical and ultrasound criteria. After confirmation of >50% narrowing by venography, participants were randomized 1:1 to receive balloon or sham venoplasty of all stenoses and were followed for 48 weeks. Participants and research staff were blinded to intervention allocation. The primary safety outcome was the number of adverse events (AEs) during 48 weeks. The primary efficacy outcome was the change from baseline to week 48 in the patient-reported outcome MS Quality of Life–54 (MSQOL-54) questionnaire. Standardized clinical and MRI outcomes were also evaluated.ResultsOne hundred four participants were randomized (55 sham; 49 venoplasty) and 103 completed 48 weeks of follow-up. Twenty-three sham and 21 venoplasty participants reported at least 1 AE; one sham (2%) and 5 (10%) venoplasty participants had a serious AE. The mean improvement in MSQOL-54 physical score was +1.3 (sham) and +1.4 (venoplasty) (p = 0.95); MSQOL-54 mental score was +1.2 (sham) and −0.8 (venoplasty) (p = 0.55).ConclusionsOur data do not support the continued use of venoplasty of extracranial jugular and/or azygous venous narrowing to improve patient-reported outcomes, chronic MS symptoms, or the disease course of MS.ClinicalTrials.gov identifierNCT01864941.Classification of evidenceThis study provides Class I evidence that for patients with MS, balloon venoplasty of extracranial jugular and azygous veins is not beneficial in improving patient-reported, standardized clinical, or MRI outcomes.

Symptom-Oriented Follow-Up of Early Breast Cancer Is not Inferior to Conventional Control. Results of a Prospective Multicentre Study

2007 ◽  
Vol 30 (8-9) ◽  
pp. 443-449 ◽  
Author(s):  
Sven Bornhak ◽  
Else Heidemann ◽  
Hans-Joachim Herschlein ◽  
Wolfgang Simon ◽  
Elisabeth Merkle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multicentre Study ◽  
Early Breast Cancer ◽  
Prospective Multicentre Study

Endoscopic Fundoplication

2017 ◽  
Vol 12 (3) ◽  
pp. 180-185 ◽  
Author(s):  
Michael I. Ebright ◽  
Praveen Sridhar ◽  
Virginia R. Litle ◽  
Chaitan K. Narsule ◽  
Benedict D. Daly ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Health Related Quality ◽  
Atypical Symptoms ◽  
Related Quality ◽  
Health Related ◽  
Quality Of Life Index ◽  
Grade 3 ◽  
Laparoscopic Techniques

Objective Transoral incisionless fundoplication (TIF) is a completely endoscopic approach to treat gastroesophageal reflux disease (GERD). We previously reported our initial results demonstrating safety and early effectiveness. We now present an updated experience describing outcomes with longer follow-up. Methods For a three-year period, TIF procedures were performed on 80 patients. Preoperative workup routinely consisted of contrast esophagram and manometry. PH testing was reserved for patients with either atypical symptoms or typical symptoms unresponsive to protonpump inhibitors (PPIs). Heartburn severity was longitudinally assessed using the GERD health-related quality of life index. Safety analysis was performed on all 80 patients, and an effectiveness analysis was performed on patients with at least 6-month follow-up. Results Mean procedure time was 75 minutes. There were seven (8.75%) grade 2 complications and one (1.25%) grade 3 complication (aspiration pneumonia). The median length of stay was 1 day (mean, 1.4). Forty-one patients had a minimum of 6-month of follow-up (mean, 24 months; range, 6–68 months). The mean satisfaction scores at follow-up improved significantly from baseline ( P < 0.001). Sixty-three percent of patients had completely stopped or reduced their PPI dose. Results were not impacted by impaired motility; however, the presence of a small hiatal hernia or a Hill grade 2/4 valve was associated with reduced GERD health-related quality of life scores postoperatively. Conclusions At a mean follow-up of 24 months, TIF is effective. Although symptoms and satisfaction improved significantly, many patients continued to take PPIs. Future studies should focus on longer-term durability and comparisons with laparoscopic techniques.

Sign in / Sign up

Export Citation Format

Share Document